The paradigm shift to an “open” model in drug development

Publication date: Available online 16 September 2014 Source:Applied & Translational Genomics Author(s): Regina Au The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount of time and money in developing a drug that will have a significant return on investment (ROI) it has become hard to sustain a robust pipeline. The industry is transforming its business model to meet these challenges. In essence a paradigm shift is occurring; the old “closed” model is giving way to a new “open” business model.
Source: Applied and Translational Genomics - Category: Genetics & Stem Cells Source Type: research